Umbelliferone aminoalkyl derivatives, a new class of squalene-hopene cyclase inhibitors. 2004

Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
Dip. to di Scienza e Tecnologia del Farmaco, Università di Torino, via Giuria 9, 10125 Turin, Italy. giancarlo.cravotto@unito.it

The synthesis is described of several aminoalkyl derivatives of coumarin, obtained in good yields under microwave or high-intensity ultrasound irradiation. These compounds proved uniformly active as inhibitors of squalene-hopene cyclase (SHC) from Alicyclobacillus acidocaldarius. Their design stemmed from our recent finding that the umbelliferone nucleus acquires inhibitory properties towards SHC when functionalized with a suitable chain such as the omega-epoxyfarnesyl group. Under our experimental conditions the most active ones, such as 7-(4'-allylmethylamino-but-2-ynyloxy)chromen-2-one (IC(50) 0.75 mM), approached the potency of anticholesteremic drug Ro 48-8071 (IC(50) 0.35 mM), an effective inhibitor of both squalene- and oxidosqualene-cyclases (OSC). Tests are in progress to determine their efficacy on different eukaryotic OSCs.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000924 Anticholesteremic Agents Substances used to lower plasma CHOLESTEROL levels. Cholesterol Inhibitors,Hypocholesteremic Agents,Anticholesteremic Drugs,Anticholesteremics,Inhibitors, Cholesterol,Agents, Anticholesteremic,Agents, Hypocholesteremic,Drugs, Anticholesteremic
D001406 Bacillaceae A family of bacteria which produce endospores. They are mostly saprophytes from soil, but a few are insect or animal parasites or pathogens.
D001577 Benzophenones Derivatives of benzophenone (with the structural formula phenyl-(C
D013185 Squalene A natural 30-carbon triterpene.
D013552 Swine Any of various animals that constitute the family Suidae and comprise stout-bodied, short-legged omnivorous mammals with thick skin, usually covered with coarse bristles, a rather long mobile snout, and small tail. Included are the genera Babyrousa, Phacochoerus (wart hogs), and Sus, the latter containing the domestic pig (see SUS SCROFA). Phacochoerus,Pigs,Suidae,Warthogs,Wart Hogs,Hog, Wart,Hogs, Wart,Wart Hog
D014468 Umbelliferones 7-Hydroxycoumarins. Substances present in many plants, especially umbelliferae. Umbelliferones are used in sunscreen preparations and may be mutagenic. Their derivatives are used in liver therapy, as reagents, plant growth factors, sunscreens, insecticides, parasiticides, choleretics, spasmolytics, etc. 7-Hydroxycoumarins,Hydrangin,Skimmetin,7 Hydroxycoumarins
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
July 1999, The Journal of organic chemistry,
Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
July 2005, Lipids,
Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
May 2003, Journal of medicinal chemistry,
Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
January 2020, Frontiers in bioengineering and biotechnology,
Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
February 2002, Chemical communications (Cambridge, England),
Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
March 2000, Lipids,
Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
November 1990, European journal of biochemistry,
Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
October 2022, Nature communications,
Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
June 2011, Applied and environmental microbiology,
Giancarlo Cravotto, and Gianni Balliano, and Silvia Tagliapietra, and Giovanni Palmisano, and Andrea Penoni
February 2000, FEMS microbiology letters,
Copied contents to your clipboard!